Journal article icon

Journal article

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Abstract:

Background: Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint. Methods: In a multicentre, 2×2 factorial, non-inferiority randomised trial, we enrolled adults aged at least 50 years with active, previous...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1016/S0140-6736(13)61501-9

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Neuroscience
Role:
Author
Expand authors...
National Institute for Health Research More from this funder
Publisher:
Elsevier Publisher's website
Journal:
The Lancet Journal website
Volume:
382
Issue:
9900
Pages:
1258-1267
Publication date:
2013-01-01
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
URN:
uuid:06121ca7-8e18-4e11-864a-4aa0255262e1
Source identifiers:
415330
Local pid:
pubs:415330
Language:
English

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP